Viatris(US:VTRS) GlobeNewswire News Roomยท2025-06-02 17:12Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Viatris, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information impacting the company's revenue outlook and growth projections [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Viatris [2]. - The complaint alleges that Viatris and its executives made false statements and failed to disclose significant risks related to a failed FDA inspection at its Indore facility, which adversely affected the company's financial outlook [4]. - The class action lawsuit claims that Viatris downplayed the impact of the FDA inspection and the resulting remediation efforts, which significantly hindered the company's ability to manufacture and ship key products [4]. Group 2: Financial Impact and Stock Performance - On February 27, 2025, Viatris announced disappointing financial results for Q4 and full fiscal year 2024, attributing below-expectation guidance to the financial impact from the Indore facility's warning letter and import alert [5]. - Following the announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, marking a decline of approximately 15.21% in one day [6].